You are here: Industry Insights > Genentech

News List

Corvus, Genentech Expand Clinical Collaboration contractpharma
May 03, 2017
To evaluate CPI-444 in combination with Atezolizumab in non-small cell lung cancer
FDA approves Genentech’s Lucentis for diabetic retinopathy cphi-online
April 21, 2017
First and only medicine FDA-approved to treat all forms of diabetic retinopathy.
Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemo americanpharmaceuticalreview
April 18, 2017
Genentech has announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII.
Genentech’s Alecensa superior to crizotinib in certain Lung Cancer: study biospectrumasia
April 11, 2017
Alecensa was granted accelerated approval by the FDA in December 2015 for the treatment of people with ALK-positive NSCLC
FDA approves Genentech’s Ocrevus for relapsing and primary progressive forms of MS cphi-online
March 31, 2017
An important new treatment option for people with relapsing forms of multiple sclerosis demonstrating superior efficacy on the three major markers of disease activity compared with Rebif.
FDA approves Genentech’s Ocrevus for relapsing and primary progressive forms of MS cphi-online
March 30, 2017
The FDA has approved Genentech's Ocrevus (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis (MS).
Mylan announces global settlement and license Agreements with Genentech and Roche on Herceptin cphi-online
March 15, 2017
Settlement provides Mylan with global licenses for its trastuzumab product.
Phase II study supports potential for Genentech’s Tecentriq plus Avastin for people with mRCC cphi-online
February 21, 2017
Study showed that people whose disease expressed PD-L1 and were treated with Tecentriq plus Avastin had a 36% reduction in the risk of their disease worsening
US FDA accepts Genentech Actemra’s sBLA for Giant Cell Arteritis pharmaceutical-technology
January 26, 2017
The US Food and Drug Administration (FDA) has accepted Genentech’s supplemental biologics licence application (sBLA) for Actemra (tocilizumab) for the treatment of Giant Cell Arteritis (GCA).
FDA Grants Priority Review for Genentech’s Actemra® sBLA for Giant Cell Arteritis, a Form of Vasculi americanpharmaceuticalreview
January 25, 2017
Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics License Application (sBLA) for Actemra® (tocilizumab) for the treatment of GCA, a chronic, potentially life-threatening autoimmune condi

Previous page 1 2 3 4 5 6 7 8 Next page